Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerebroside + carnosine (Chinese name: 脑苷肌肽) is a combination drug formulation used primarily in China as a neurotrophic agent. It contains two main components: - **Cerebrosides** are glycosphingolipids found in animal nerve tissue, believed to support neuronal repair and regeneration. - **Carnosine** is a naturally occurring dipeptide (beta-alanyl-L-histidine) with antioxidant, anti-glycation, and metal-chelating properties. Carnosine is concentrated in muscle and brain tissues and has been studied for its neuroprotective effects[1][2][5]. This combination is typically administered by injection for the treatment of neurological conditions such as stroke recovery, peripheral facial paralysis (Bell’s palsy), traumatic brain injury, or other central nervous system disorders where neuroprotection or neural repair is desired[4]. The mechanism of action involves antioxidation (carnosine), membrane stabilization, promotion of neuronal survival and repair (cerebrosides), and possible modulation of neurotransmitter systems.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cerebroside + carnosine.